{"id":"NCT00477269","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension","officialTitle":"A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of the Six Months Treatment With the Tyrosine Kinase Inhibitor STI571 for the Treatment of Pulmonary Arterial Hypertension (PAH)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-04","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2007-05-23","resultsPosted":"2015-03-23","lastUpdate":"2015-03-23"},"enrollment":59,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Imatinib mesylate","otherNames":["Imatinib, Glivec, Gleevec, STI571, QTI571"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"STI571","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"All Patients","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension","primaryOutcome":{"measure":"Number of Patients With Adverse Events (AEs), Serious Adverse Events (SAEs) and Death During the Core","timeFrame":"6 months","effectByArm":[{"arm":"STI571","deltaMin":27,"sd":null},{"arm":"Placebo","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":13,"countries":["United States","Austria","Germany","United Kingdom"]},"refs":{"pmids":["20581169"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":28},"commonTop":["Nasopharyngitis","Nausea","Oedema peripheral","Headache","Diarrhoea"]}}